Trial Profile
Multicenter randomised open label study of Paritaprevir Plus Ritonavir Plus Ombitasvir in the Treatment of HCV Genotype 4-Infected Patients with Stage 4-5 Chronic Kidney Disease in Saudi Arabia
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Dec 2018
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 11 Dec 2018 New trial record
- 13 Nov 2018 Results (n=43) presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases